A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer
Abstract
Inflammation and one of its mediators, NF‐kappa B (NFκB), have been implicated in prostate cancer carcinogenesis. We assessed whether germline polymorphisms associated with NFκB are associated with the risk of developing lethal disease (metastases or death from prostate cancer).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 06, 2021
- Source ID
- 10.1002/pros.24148
Entities
People
- Ana Vega
- Anis A Hamid
- Christopher Sweeney
- Curtis Huttenhower
- Daniela Börnigen
- Frank Claessens
- Gwo‐Shu Mary Lee
- Huma Rana
- Janet L. Stanford
- Jong Y Park
- Karina D. Sørensen
- Kathryn L. Penney
- Kristina M. Jordahl
- Lorelei A. Mucci
- Mark Pomerantz
- Matthew L Freedman
- Milan S. Geybels
- Nawaid Usmani
- Ros A. Eeles
- Sarah C Markt
- Sonja I. Berndt
- The Practical Consortium
- Timothy R Rebbeck
- Travis Gerke
- Victoria Wang
Organizations
- Aarhus University
- Broad Institute
- Case Western Reserve University
- Congressionally Directed Medical Research Programs
- Dana–Farber Cancer Institute
- H. Lee Moffitt Cancer Center & Research Institute
- Harvard Medical School
- Harvard T.H. Chan School of Public Health
- Harvard University
- Institute of Cancer Research
- Katholieke Universiteit Leuven
- Maastricht University
- National Cancer Institute
- The Royal Marsden NHS Foundation Trust
- University Medical Center Hamburg-Eppendorf
- University of Alberta